» Articles » PMID: 24449819

Does Transendocardial Injection of Mesenchymal Stem Cells Improve Myocardial Function Locally or Globally?: An Analysis from the Percutaneous Stem Cell Injection Delivery Effects on Neomyogenesis (POSEIDON) Randomized Trial

Abstract

Rationale: Transendocardial stem cell injection (TESI) with mesenchymal stem cells improves remodeling in chronic ischemic cardiomyopathy, but the effect of the injection site remains unknown.

Objective: To address whether TESI exerts its effects at the site of injection only or also in remote areas, we hypothesized that segmental myocardial scar and segmental ejection fraction improve to a greater extent in injected than in noninjected segments.

Methods And Results: Biplane ventriculographic and endocardial tracings were recorded. TESI was guided to 10 sites in infarct-border zones. Sites were mapped according to the 17-myocardial segment model. As a result, 510 segments were analyzed in 30 patients before and 13 months after TESI. Segmental early enhancement defect (a measure of scar size) was reduced by TESI in both injected (-43.7 ± 4.4%; n=95; P<0.01) and noninjected segments (-25.1 ± 7.8%; n=148; P<0.001; between-group comparison P<0.05). Conversely, segmental ejection fraction (a measure of contractile performance) improved in injected scar segments (19.9 ± 3.3-26.3 ± 3.5%; P=0.003) but not in noninjected scar segments (21.3 ± 2.6-23.5 ± 3.2%; P=0.20; between-group comparison P<0.05). Furthermore, segmental ejection fraction in injected scar segments improved to a greater degree in patients with baseline segmental ejection fraction <20% (12.1 ± 1.2-19.9 ± 2.7%; n=18; P=0.003), versus <20% (31.7 ± 3.4-35.5 ± 3.3%; n=12; P=0.33, between-group comparison P<0.0001).

Conclusions: These findings illustrate a dichotomy in regional responses to TESI. Although scar size reduction was evident in all scar segments, scar size reduction and ventricular functional responses preferentially occurred at the sites of TESI versus non-TESI sites. Furthermore, improvement was greatest when segmental left ventricular dysfunction was severe.

Citing Articles

Genetically modified mesenchymal stromal cells: a cell-based therapy offering more efficient repair after myocardial infarction.

Xu C, Xie Y, Wang B Stem Cell Res Ther. 2024; 15(1):323.

PMID: 39334266 PMC: 11438184. DOI: 10.1186/s13287-024-03942-7.


Mesenchymal Stem Cell-Derived Exosomal microRNAs in Cardiac Regeneration.

Bhaskara M, Anjorin O, Wang M Cells. 2023; 12(24).

PMID: 38132135 PMC: 10742005. DOI: 10.3390/cells12242815.


Cell Therapy in the Treatment of Coronary Heart Disease.

Chepeleva E Int J Mol Sci. 2023; 24(23).

PMID: 38069167 PMC: 10706847. DOI: 10.3390/ijms242316844.


Bioengineering for vascularization: Trends and directions of photocrosslinkable gelatin methacrylate hydrogels.

Im G, Lin R Front Bioeng Biotechnol. 2022; 10:1053491.

PMID: 36466323 PMC: 9713639. DOI: 10.3389/fbioe.2022.1053491.


Opportunities and challenges in stem cell therapy in cardiovascular diseases: Position standing in 2022.

Mahmud S, Alam S, Emon N, Boby U, Kamruzzaman , Ahmed F Saudi Pharm J. 2022; 30(9):1360-1371.

PMID: 36249945 PMC: 9563042. DOI: 10.1016/j.jsps.2022.06.017.


References
1.
Mahnken A, Koos R, Katoh M, Wildberger J, Spuentrup E, Buecker A . Assessment of myocardial viability in reperfused acute myocardial infarction using 16-slice computed tomography in comparison to magnetic resonance imaging. J Am Coll Cardiol. 2005; 45(12):2042-7. DOI: 10.1016/j.jacc.2005.03.035. View

2.
Williams A, Suncion V, McCall F, Guerra D, Mather J, Zambrano J . Durable scar size reduction due to allogeneic mesenchymal stem cell therapy regulates whole-chamber remodeling. J Am Heart Assoc. 2013; 2(3):e000140. PMC: 3698774. DOI: 10.1161/JAHA.113.000140. View

3.
Karantalis V, DiFede D, Gerstenblith G, Pham S, Symes J, Zambrano J . Autologous mesenchymal stem cells produce concordant improvements in regional function, tissue perfusion, and fibrotic burden when administered to patients undergoing coronary artery bypass grafting: The Prospective Randomized Study of Mesenchymal.... Circ Res. 2014; 114(8):1302-10. PMC: 4104798. DOI: 10.1161/CIRCRESAHA.114.303180. View

4.
Schuleri K, Feigenbaum G, Centola M, Weiss E, Zimmet J, Turney J . Autologous mesenchymal stem cells produce reverse remodelling in chronic ischaemic cardiomyopathy. Eur Heart J. 2009; 30(22):2722-32. PMC: 2777027. DOI: 10.1093/eurheartj/ehp265. View

5.
Kocher A, Schuster M, Szabolcs M, Takuma S, Burkhoff D, Wang J . Neovascularization of ischemic myocardium by human bone-marrow-derived angioblasts prevents cardiomyocyte apoptosis, reduces remodeling and improves cardiac function. Nat Med. 2001; 7(4):430-6. DOI: 10.1038/86498. View